Pre-clinical studies10

The use of Hemoflex® on an external arterial and venous bleeding model representing a standard injury of the upper third of thigh with complete ransection of the pig’s femoral artery and vein considerably decreased the bleeding time and blood loss mass compared to the control group: this proves a clear hemostatic effect.

Intraoperative blood loss mass.

Hemoflex®

248g

The control group

396g

Microbiological studies11

Hemoflex® features a clear antimicrobial / bactericidal effect to testing cultures S. Aureus ATCC 29213, E. Coli ATCC 25922, S. Pyogenes clinical isolate), Myc. Smegmatis ATCC 437RW, and C. Albicans ATCC 90028.

Culture

Contact time (H)

Control

3

6

8

12

24

S. Aureus ATCC 29213

-

-

-

-

-

480 colonies

E. Coli ATCC 25922

10 colonies

-

-

-

-

95 colonies

S. Pyogenes (clinical isolate)

20 colonies

17 colonies

4 colonies

-

-

27 colonies

C. Albicans ATCC 90028

-

-

-

-

-

6 colonies

Myc. Smegmatis ATCC 437RW

±±

±±

±

-

-

±±

Clinical testing12

Chart

The use of Hemoflex® for control of external arterial, venous and capillary bleeding in groin surgery produced a hemostatic effect in all the cases. No rebleeding was observed after removal of the product out of the wound, and no undesirable side effects including allergies were recorded.